- Author
- Akshay Maheshwari, CEO, b.next
- Published
- Undated
- Kind
- Company blog post about its own manufacturing work
- Original
- bnext.bio/post/we-accidentally-built-a-synthetic-cell-factory
- Subject
- Science and medicine
What it is
Akshay Maheshwari is CEO of b.next, a San Francisco company. The post recounts the move from an open platform, Nucleus, to making Cytosol kits. It aims to explain why the firm took on manufacturing.
What it says
- Maheshwari says b.next began to fix interoperability and integration in synthetic cell research.
- The post says the team could not obtain the 36 plasmids for open PURE.
- It says only a handful of labs had built PURE, often taking over 18 months.
- It says tRNA supply stopped when Roche, and then Sigma, ceased supplying it.
- The post says nine months of work produced detectable output from the open PURE system.
- It says a San Francisco plant now makes Cytosol kits to open Nucleus specifications.
- It says over a hundred kits have supported open projects at about 20 labs.
What evidence it gives
The evidence is the company's own account. It gives a few figures. These are nine months to detectable output, a 100th kit, and about 20 labs. It shows no test data on the kits.
Interests and limits
The author runs the company that makes and sells the kits. No outside lab or measurement backs the claims. The supply problems with tRNA are told from the company's side only. The post carries no date.